Live Breaking News & Updates on Promedico ltd

Stay informed with the latest breaking news from Promedico ltd on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Promedico ltd and stay connected to the pulse of your community

Form 10-Q Karyopharm Therapeutics For: Sep 30

Form 10-Q Karyopharm Therapeutics For: Sep 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massachusetts , United-states , United-kingdom , New-hampshire , Connecticut , Taiwan , Boston , Switzerland , North-dakota , Delaware , Maine , Israel

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...

Australia , United-states , United-kingdom , Israel , Singapore , China , Boston , Massachusetts , Sadal , Kyongsang-bukto , South-korea , American

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

China , Boston , Massachusetts , United-states , Sadal , Kyongsang-bukto , South-korea , United-kingdom , Israel , Israeli , American , Peterk-honig

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering...

China , Boston , Massachusetts , United-states , Sadal , Kyongsang-bukto , South-korea , United-kingdom , Israel , Israeli , American , Peterk-honig

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering...

China , Boston , Massachusetts , United-states , Sadal , Kyongsang-bukto , South-korea , United-kingdom , Israel , Israeli , American , Peterk-honig

JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track

JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track
NEW BRUNSWICK (dpa-AFX) - Today's Daily Dose brings you news about Johnson & Johnson seeking FDA nod for its single-shot COVID-19 vaccine candidate, T2 Biosystems' molecular diagnostic test detecting Brazil variant of the SARS-CoV-2 virus, Sientra' better-than-expected Q4 preliminary revenue results, Karyopharm securing approval for XPOVIO in Israel and resignation of Merck's CEO.
Read on.
1. JNJ Seeks emergency FDA Nod For COVID-19 Vaccine
Johnson & Johnson (JNJ) has submitted an application to the FDA, seeking Emergency Use Authorization of its single-shot COVID-19 vaccine candidate.
In a phase III trial, dubbed ENSEMBLE, which included participants from different geographies and including those infected with an emerging viral variant, Janssen's COVID-19 vaccine candidate was 66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination.

Brazil , South-africa , United-states , Israel , Brunswick , Niedersachsen , Germany , America , Palestinian , Kenneth-frazier , Robert-davis , Midatech-pharma

Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Share this article
Share this article
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health, Israel's regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved indications for XPOVIO are a) in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and b) for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

Boston , Massachusetts , United-states , Israel , Israeli , Palestinian , Sharon-shacham , Selective-inhibitor-of-nuclear-export , Takeda-pharmaceutical-company , Nasdaq , European-union , Karyopharm-selective-inhibitor-of-nuclear-export